La Jolla Pharma, Leo Pharmaceutical Products Ltd. deal

LJPC terminated its agreement for Leo to market LJPC's LJP 394 lupus drug candidate in Europe and the Middle East. Following positive results of a dose-ranging Phase II study announced in the first quarter (see BioCentury, Feb. 20.), LJPC said the companies could not come to terms on the timing and financial issues for subsequent trials. ...